While immune checkpoint inhibitors (ICIs) targeting the PD-1 or CTLA-4 have achieved great success in the field of lung cancer in recent years, the efficacy of ICIs remains suboptimal, with only a fraction of patients responding positively and benefit from ICIs [3–5]. The gene discussed is CTLA4; the disease is lung cancer.